SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending after an earnings report delivered an EPS beat but missed on adjusted EBITDA and offered vague guidance, sparking intense community debate. Bears are pointing to alleged accounting fraud, non-cash earnings, and evasive management on "related party transactions" amidst SEC scrutiny, while some bulls view the significant stock drop as an overreaction.

B2Gold Corp. is an exploration company, which engages in the acquisition and development of mineral properties. It operates through the following segments: Fekola Mine, Fekola Regional, Masbate Mine, Otjikoto Mine, Goose Project, Other Mineral Properties, and Corporate and Other. The Fekola Regional segment consists of Bantako North, Menankoto, Dandoko, and Bakolobi properties. The Other Mineral Properties segment focuses on the company interests in mineral properties which are at various stages of exploration and evaluation. The Corporate and Other segment includes the corporate operations. The company was founded by Mark Anthony Corra, Thomas A. Garagan, Clive Thomas Johnson, and Roger Thomas Richer on November 30, 2006 and is headquartered in Vancouver, Canada.

B2gold Corp

B2Gold is a major talking point as investors react to perceived weak guidance and delayed Fekola permit updates, leading to widespread frustration with management despite soaring gold prices that many argue make the stock significantly undervalued compared to its peers.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is seeing significant conversation after its latest earnings exceeded expectations, signaling accelerating growth and robust net dollar retention, leading many to believe AI is expanding, not diminishing, its market and driving short squeeze speculation for a strong rebound.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending due to a perplexing surge in its stock despite missing recent earnings and revenue estimates, sparking widespread debate among traders. The community is divided between those attributing the unexpected rally to a short squeeze or algo manipulation, and others highlighting strong future guidance as the surprising catalyst.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following a strong earnings report that exceeded expectations and the strategic acquisition of Depop from Etsy, aiming to boost its consumer-to-consumer strategy and attract younger buyers. The community is actively discussing eBay's robust financial performance, increased shareholder returns, and how AI integrations and a focus on high-value categories are driving conversation about its future growth.

Etsy, Inc. engages in the operation of an online marketplace. It offers handmade products such as shoes, clothing, bags, and accessories. It operates through the following segments: Etsy, Reverb, and Depop. The company was founded in 2005 and is headquartered in New York, NY.

Etsy Inc

Etsy is trending following the announcement of its Depop sale to eBay for $1.2 billion, which is generating mixed reactions. While many investors are optimistic about the significant cash infusion and Etsy's sharpened focus on its core marketplace, some in the community are critical of the divestment given its original acquisition cost.

Booking Holdings, Inc. engages in the provision of online travel and related solutions. The firm offers services through the following brands: Booking.com, Priceline, Agoda, KAYAK, and OpenTable. It provides accommodation reservations including hotels, hostels, apartments, vacation rentals, and other properties. The company was founded by Jay Scott Walker on July 18, 1997, and is headquartered in Norwalk, CT.

Booking Holdings Inc

Booking Holdings is generating significant buzz due to a strong earnings beat, optimistic future guidance, and a dividend increase, coupled with a 25-for-1 stock split announcement that has the community actively debating accessibility versus historical post-split performance and AI competition risks.

Coeur Mining, Inc. engages in the well-diversified, growing precious metals producer with a focus on generating sustainable, high-quality cash flow and returns from a balanced, prospective asset base in mining-friendly jurisdictions along with commitment to exploration and expansions. It operates through the following segments: Palmarejo, Rochester, Kensington, Wharf and Silvertip. The Palmarejo segment includes a gold-silver complex. The Rochester segment operates an open pit heap leach silver-gold mine in northwestern Nevada. The Kensington segment relates to an underground gold mine located north of Juneau, Alaska. The Wharf segment focuses on an open pit heap leach gold mine located near Lead, South Dakota. The Silvertip segment silver-zinc-lead exploration located in the state of Sonora in northern Mexico. The company was founded in 1928 and is headquartered in Chicago, IL.

Coeur Mining Inc

Coeur Mining Inc. is trending after announcing strong Q4 earnings, revenue, and optimistic 2026 production guidance, which is further bolstered by the approved New Gold merger. The community is actively discussing the stock's perceived undervaluation and market manipulation, believing its price should reflect the robust financial outlook and surging precious metal prices.

Remitly Global, Inc. engages in the provision of digital financial services for immigrants and their families. The company was founded by Matthew B. Oppenheimer and Joshua Hug on October 3, 2018 and is headquartered in Seattle, WA.

Remitly Global Inc

Remitly Global is trending following a strong earnings report that exceeded revenue and EPS expectations, along with optimistic FY26 guidance and a new CEO announcement. The community is actively discussing the company's strategic focus on AI and stablecoins, viewing them as significant tailwinds for efficiency and long-term growth in the vast global remittance market.

Borr Drilling Ltd. engages in the provision of offshore drilling services to the oil and gas industry. It operates through Dayrate; and Integrated Well Services (IWS) segments. The Dayrate segment consists of rig charters and ancillary services. The IWS segment provides integrated well services through Opex and Akal. The company was founded by Tor Olav Trøim on August 8, 2016 and is headquartered in Hamilton, Bermuda.

Borr Drilling Ltd

Borr Drilling is seeing increased attention following new contract commitments for two jack-up rigs, extending firm contracts into 2026/2027 and pushing its fleet utilization to 23 out of 24 active units. The community is actively discussing this as a positive for future revenue visibility and market position, amidst a tightening offshore drilling market and geopolitical tailwinds.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company had previously said that it expects to submit an application for approval of the therapy in the first quarter of 2026.</li><li>In the December meeting with the FDA, the company discussed its clinical data and regulatory strategy.&nbsp;</li><li>In the second meeting, in January, it discussed chemistry, manufacturing, and controls (CMC) requirements.</li></ul>Shares of Spruce Biosciences, Inc. (SPRB) fell 8% on Wednesday after the company pushed back on its timeline to submit an application to the U.S. Food and Drug Administration seeking approval for its enzyme replacement therapy in patients with Sanfilippo Syndrome Type B.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260218269143/en/Spruce-Biosciences-Announces-Positive-Type-B-Meetings-with-U.S.-FDA-for-TA-ERT-for-the-Treatment-of-Sanfilippo-Syndrome-Type-B-MPS-IIIB">said</a> that it completed two meetings with the FDA regarding its planned upcoming biologics license application (BLA) submission for tralesinidase alfa enzyme replacement therapy (TA-ERT) in the treatment of Sanfilippo syndrome type B.While the first meeting was held in Dec. 2025, the second was held in Jan. 2026. In the December meeting, the company discussed its clinical data and regulatory strategy, while in the second meeting, it discussed chemistry, manufacturing, and controls (CMC) requirements.The company now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in the meetings. Spruce Biosciences had previously said that it expects to submit an application for approval of the therapy in the first quarter of 2026.<h2 class="st-heading-2">About Sanfilippo syndrome type B</h2>Sanfilippo syndrome type B (MPS IIIB) is a rare, inherited lysosomal storage disease caused by a deficiency in the enzyme alpha-N-acetylglucosaminidase, leading to the accumulation of heparan sulfate in cells, particularly neurons. It causes progressive neurological symptoms like cognitive and developmental impairment, hyperactivity with aggressive and destructive behavior, delayed speech, hearing loss, and motor skill deficits.Tralesinidase Alfa Enzyme Replacement Therapy is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB.“While the timing of our submission is now expected in the fourth quarter of this year, we believe in the strength of our long-term data for TA-ERT which demonstrates that reductions in CSF HS-NRE are associated with meaningful clinical benefits across cognition, communication, and motor skill acquisition,” CEO Javier Szwarcberg said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around SPRB stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<a href="https://stocktwits.com/symbol/SPRB">SPRB stock</a> has gained nearly 372% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-mbrx-stock-climb-today/cZR0CkIR4vA">Why Did MBRX Stock Climb 14% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ADIL’s stock has declined 75% over the past 12 months.

SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy 

Spruce Biosciences now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in meetings.

Equity

Spruce Biosciences now anticipates making the submission for TA-ERT in the fourth quarter of 2026 to accommodate the clinical and other requirements flagged by the FDA in meetings.


Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Long-Term Data Presented at the 22nd Annual WORLDSymposium Highlights Tralesinidase Alfa Enzyme Replacement Therapys Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Rating of "Hold" from Brokerages

Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) have been given a consensus recommendation of "Hold" by the nine brokerages that are presently covering the stock, MarketBeat.com...

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences

Harbour BioMed exercises its warrant to buy Spruce Biosciences shares, raising its stake to about 3.8% as the companies work together on the SPR202 drug program.read more...

Harbour BioMed Exercises Warrant To Acquire Stake In Spruce Biosciences

(RTTNews) - Harbour BioMed announced that, through its wholly-owned subsidiary, it has exercised its warrant to acquire common stock in Spruce Biosciences Inc. (SPRB). As a result of this...

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration

Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration PR Newswire...

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet...

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $WMT earnings on Thursday?

Current Price	$53.48
Prev Close	$58.25
Open	$60.76
Dividend Yield	0.00%
50-Day Moving Average	$80.29
Beta	1.05
Avg. Volume	29,516.10
PE Ratio	-0.69

52-Week High	$240.00
52-Week Low	$4.28
Market Capitalization	$62.34M
EPS (Annual)	-$96.39
Price to Book	6.09
Revenue Per Employee	$233,857.14

SPRB
Spruce Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SPRB News

SPRBSpruce Biosciences Inc